REG - e-Therapeutics plc - Director Dealing and Issue of Equity

E-TherapeuticsAnnouncement

05/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220705:nRSE2832Ra&default-theme=true

RNS Number : 2832R  e-Therapeutics plc  05 July 2022

E-THERAPEUTICS PLC

 

("e-therapeutics" or the "Company")

 

DIRECTOR DEALING AND ISSUE OF EQUITY

 

London, UK, 5 July 2022 - e-therapeutics plc (AIM: ETX), the drug discovery
company, announces that on 4 July 2022, Professor Trevor Jones (Non-Executive
Chairman of the Company) subscribed for a total of 43,913 new ordinary shares
of 0.1p each in the Company (the "New Ordinary Shares") at a price of 17.22
pence per share. The subscription monies paid for the New Ordinary Shares
represent 50% of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 January 2022 to 30 June 2022 in accordance with the
agreement entered into with Professor Jones, previously announced on 5 October
2016, by which Professor Jones agreed, with effect from 1 October 2016, to
invest 50% of his annual Non-Executive Director fees net of tax in new
e-therapeutics' ordinary shares. Such new shares are issued to Professor Jones
on the first business day after 31 December and 30 June in each year. The
subscription price to be paid is the average of the closing mid-market price
for the five business days prior to the date of issue.

 

Following Admission, Professor Jones will be interested in a total of
1,123,391 ordinary shares of 0.1p in the Company, representing approximately
0.22% of the Company's issued share capital.

 

Application has been made to AIM for the admission of the New Ordinary Shares
to trading on AIM ("Admission") and Admission is expected to occur at 8:00
a.m. on or around 11 July 2022. The New Ordinary Shares will rank pari passu
in all respects with the Company's existing ordinary shares in issue.

 

Following Admission, the total number of ordinary shares in the Company with
voting rights in issue will be 514,614,982. This figure may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the Financial Conduct Authority's
Disclosure and Transparency Rules.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further details:

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Trevor Jones
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification/ Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         e-therapeutics plc
 b)  LEI                                                          21380049RHSSJXWKYT18
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.1 pence

     Identification code

                                                                  ISIN: GB00B2823H99
 b)  Nature of the transaction                                    Purchase of shares
 c)  Price(s) and volume(s)                                       43,913 ordinary shares at a price of 17.22 pence per share
 d)  Aggregated information                                       43,913 ordinary shares

     - Aggregated volume                                          17.22 pence per share

     - Price                                                      Aggregated value: £7,561.82

 e)  Date of the transaction                                      4 July 2022

 f)  Place of the transaction                                     Outside a trading venue

 

 

For further information, please contact:

 

 e-therapeutics plc
 Ali Mortazavi, CEO                                 Tel: +44 (0)1993 883 125

 Laura Roca-Alonso, CBO                             www.etherapeutics.co.uk (http://www.etherapeutics.co.uk)

 SP Angel Corporate Finance LLP
 Nominated Adviser and Broker                       Tel: +44(0)20 3470 0470
 Matthew Johnson/Caroline Rowe (Corporate Finance)
 Vadim Alexandre/Rob Rees (Corporate Broking)

 

 

About e-therapeutics plc

 

e-therapeutics plc is a UK-based company integrating computational power and
biology to accelerate the discovery of life-transforming medicines. The
Company has developed and validated a powerful, disease and modality agnostic
computational approach to drug discovery, leveraging its industry-leading
expertise in network biology to fully capture and interrogate human disease
complexity.

 

The Company's multi-disciplinary team builds computational models of
biological functions to transform the search for new medicines, interventions,
mechanisms and genetic support. Its biology-led in silico laboratory enables
rapid hypothesis generation and phenotypic screening of millions of compounds
leading to 100-1000x higher hit rates in the wet lab and successful mode of
action elucidation. Novel targets can also be identified, prioritised and
assessed. Harnessing internal target gene discoveries, e- therapeutics is
currently building an in-house pipeline of RNAi based medicines, using its
proprietary GalNAc-siRNA technology.

 

e-therapeutics has deployed and validated its disease-agnostic computational
drug discovery platform both in house and with partners, including Novo
Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFFADVISIIF